SOURCE: Proove Biosciences

Proove Biosciences

May 19, 2016 14:46 ET

Brian Meshkin of Proove Biosciences Named EY Entrepreneur of The Year® 2016 Finalist in Orange County

IRVINE, CA--(Marketwired - May 19, 2016) -  Proove Biosciences, Inc. -- the world's largest Healthcare Decision Company™ -- is pleased to announce that CEO and founder Brian Meshkin has advanced as a finalist for the EY Entrepreneur of The Year® 2016 Orange County Region after being named a semifinalist in April. The recognition follows Meshkin's recent Excellence in Entrepreneurship Award from the Orange County Business Journal.

"It is truly an honor to be among a select group of men and women who are making life-changing contributions to society not only within Orange County, but also throughout the world," says Meshkin, whose company is the commercial and educational leader in the research, investigation and development of patent-protected genetic tests that enable physicians to personalize -- and optimize -- medicine selection and dosing in order to improve outcomes for patients, providers, and insurers alike.

Now celebrating its 30th year, the EY awards program recognizes entrepreneurs in over 145 cities and 60 countries who demonstrate excellence and extraordinary success in such areas as innovation, financial performance, and personal commitment to their businesses and communities. Winners will be announced on Friday, June 17 at a formal awards gala at St. Regis Monarch Beach Resort in Dana Point, Calif., where more than 500 founders, CEOs, and other business leaders will gather.

"This comes at an important time as the opioid and prescription drug epidemic has taken center stage in the national conversation," Meshkin adds. "With proven genetic testing-based solutions and technologies that enable accurate and evidence-based medical decisions rather than trial-and-error approaches, Proove is on a mission to help reduce the risk of treatment failure, decrease costs to insurers, and relieve society of the emotional and financial burdens associated with addiction and other adverse reactions to treatment."

To learn more about Proove Biosciences, visit www.proove.com.

About EY Entrepreneur of The Year®: EY Entrepreneur of The Year is the world's most prestigious business award for entrepreneurs. The unique award makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, Entrepreneur of The Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 145 cities in more than 60 countries.

About EY: EY is a global leader in assurance, tax, transaction and advisory services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities. EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. For more information about our organization, please visit ey.com.

About Proove Biosciences: Proove Biosciences -- the world's largest Healthcare Decision Company™ -- is the commercial and educational leader in the research, investigation and development of patent-protected genetic tests that enable physicians to personalize -- and optimize -- medicine selection and dosing in order to improve outcomes for patients, providers and insurers alike. Backed by science, driven by data, confirmed with proof and supported by leading medical experts and institutions across the globe, Proove is revolutionizing personalized medicine. With a genetic testing platform that allows prescribers to assess patient metabolism, evaluate pain tolerance, response and immunity to opioid and non-opioid pain medication, and identify genetic predisposition for dependence and addiction, Proove is providing the most technologically advanced solutions to enable accurate and evidence-based medical decision-making rather than trial-and-error approaches. Proove helps reduce the risk of treatment failure, decrease costs to insurers and relieve society of the emotional and financial burdens associated with addiction. For more information, please visit www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).

Contact Information